ArticlePloS one2014
Oral manifestations in the American tegumentary leishmaniasis.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Clinical criteria for Mucosal Leishmaniasis diagnosis in rural South America: A systematic literature review.PLoS neglected tropical diseases · 2022Pooled it
- In Situ Cellular Response Underlying Successful Treatment of Mucosal Leishmaniasis with a Combination of Pentavalent Antimonial and Pentoxifylline.The American journal of tropical medicine and hygiene · 2019Trial
- Comparative Analysis of Oral and Oropharyngeal Mucosal Lesions of American Tegumentary Leishmaniasis and Other Infectious Granulomatous Diseases and Squamous Cell Carcinoma.Pathogens (Basel, Switzerland) · 2026Article
- Persistence ofBiomedicines · 2025Article
- Adequacy of nutritional status and dietary intake of adult and elderly patients with American Tegumentary Leishmaniasis.Einstein (Sao Paulo, Brazil) · 2025Article
- Article
- Mucosal Leishmaniasis of the lip: Report of an Exuberant case in a Young man.Head and neck pathology · 2023Article
- Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient.Head and neck pathology · 2021Article
- Autochthonous Cases of Mucosal Leishmaniasis in Northeastern Italy: Clinical Management and Novel Treatment Approaches.Microorganisms · 2020Article
- American tegumentary leishmaniasis: diagnostic and treatment challenges in a clinical case.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- Differentiation of mucosal lesions in mucocutaneous leishmaniasis and paracoccidioidomycosis.PloS one · 2018Article
- Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).Memorias do Instituto Oswaldo Cruz · 2017Article
- Factors Associated with Clinical and Topographical Features of Laryngeal Tuberculosis.PloS one · 2016Article
- Article
- Effect of Intralesional Sodium Stibogluconate Alone versus Combinations with Topical Trichloroacetic Acid 50% or Fractional Carbon Dioxide Laser on Cutaneous Leishmaniasis.Indian journal of dermatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAmerican tegumentary leishmaniasis (ATL) can affect the skin or mucosa (mucocutaneous leishmaniasis - MCL) including the oral cavity. MCL oral lesions are often confused with other oral diseases, delaying diagnosis and specific treatment, and increasing the likelihood of sequelae. Thus, increasing the knowledge of the evolution of ATL oral lesions can facilitate its early diagnosis improving the prognosis of healing.
objectivesEvaluate the frequency of ATL oral lesion and describe its clinical, laboratory and therapeutic peculiarities.
methodsA descriptive transversal study was carried out, using data from medical records of 206 patients with MCL examined at the outpatient clinics-IPEC-Fiocruz between 1989 and 2013. Proportions were calculated for the categorical variables and the association among them was assessed by the Pearson's chi-square test. Measures of central tendency and dispersion were used for the continuous variables and their differences were assessed by both parametric (t test) and non parametric (Mann-Whitney) tests. P-values <0.05 were considered as significant.
resultsThe most affected site was the nose, followed by the mouth, pharynx and larynx. Seventy eight (37.9%) have oral lesions and the disease presented a lower median of the evolution time than in other mucous sites as well as an increased time to heal. The presence of oral lesion was associated with: the presence of lesions in the other three mucosal sites; a smaller median of the leishmanin skin test values; a longer healing time of the mucosal lesions; a higher recurrence frequency; and a smaller frequency of treatment finishing and healing. When the oral lesion was isolated, it was associated with an age 20 years lower than when the oral lesion was associated with other mucosal sites.
conclusionConsidering the worst therapy results associated with the presence of oral lesions, we suggest that lesions in this location represent a factor of worse prognosis for MCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.